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Abstract
In modern medical care in which Kampo and Western drugs are often combined, it is extremely important to clarify drug–
drug interaction (DDI) to ensure safety and efficacy. However, there is little evidence of DDI in Kampo medicines. There-
fore, as part of our studies to clarify the DDI risk for Kampo medicines, we evaluated the effects of five Kampo medicines 
[yokukansan (YKS), rikkunshito (RKT), shakuyakukanzoto (SKT), hangeshashinto (HST), and goshajinkigan (GJG)] that are 
widely used in Japan, on drug transporter P-glycoprotein (P-gp) using a Caco-2 permeability assay. These Kampo medicines 
inhibited the P-gp transport of digoxin through a Caco-2 cell monolayer. The  IC50 values were 1.94–10.80 mg/ml. Of the five 
Kampo medicines, YKS showed the strongest inhibition  (IC50 = 1.94 mg/ml), which was attributed to Uncariae Uncis Cum 
Ramulus. Unfortunately, we could not find the active ingredients responsible for its action. Finally, the Igut/IC50 values for 
the five Kampo medicines were calculated, and the DDI risk was objectively evaluated according to the criteria in the DDI 
guidance issued by the Japanese Ministry of Health, Labor, and Welfare and the US Food and Drug Administration. The 
Igut/IC50 values for the five Kampo medicines were ≤3.4. As these values were <10, they were evaluated as having a weak 
P-gp inhibitory effect that does not require further verification in humans, suggesting that the DDI risk due to P-gp inhibi-
tion for these Kampo medicines is low. The results should provide useful clinical information on the safety and efficacy of 
the combined use of Kampo and Western medicines.
Keywords Kampo medicine · Drug–drug interaction · Drug transporter · P-glycoprotein
Introduction
Many reports have demonstrated that various metabolizing 
enzymes and transporters have important roles in the phar-
macokinetics of xenobiotics [1–4]. P-glycoprotein (P-gp) is 
one of the major drug transporters expressed in different 
organs, including the small intestine, kidney, liver, lungs, 
colon, and blood–brain barrier [5, 6]. In the small intestine, 
P-gp is localized in the apical surface of intestinal epithelial 
mucosa and has the primary function of promoting removal 
of toxic compounds by active efflux back to the intestinal 
lumen [7]. Recently, venetoclax, which is indicated for the 
treatment of patients with chronic lymphocytic leukemia, 
enhanced the plasma concentration of co-administrated 
digoxin, a P-gp probe substrate, by inhibition of P-gp trans-
porter [8]. Similarly, the levels of expression and function-
ality of P-gp can be modulated by inhibition or induction, 
which can affect the pharmacokinetics, efficacy, safety, or 
tissue levels of P-gp substrates, i.e., the safety and efficacy of 
drugs can be dramatically altered by drug–drug interactions 
(DDIs) which are influenced by the increase and decrease 
in P-gp activity.
Caco-2 cells derived from human colon carcinoma cells, 
which express P-gp and metabolizing enzymes such as 
peptidase, are widely used as an in vitro model of human 
small intestinal mucosa to predict the absorption of orally 
administered drugs [9] because of their morphological 
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and functional similarity with human enterocytes [9, 10]. 
Digoxin is often used as a model P-gp substrate to assess 
transporter-mediated transport and inhibition in the Caco-2 
permeability assay [11].
Many traditional Japanese Kampo medicines approved 
by the Japanese Ministry of Health, Labor, and Welfare 
(MHLW) have been used for the treatment of various dis-
eases in Japan for many years. In modern medical care in 
which Kampo and Western drugs are often combined, it is 
important to clarify DDI to ensure the safety and efficacy 
of their combined use. However, there is little evidence of 
DDI in Kampo medicines. Yokukansan (YKS), rikkunshito 
(RKT), hangeshashinto (HST), goshajinkigan (GJG), and 
shakuyakukanzoto (SKT) are Kampo medicines which have 
been used for treating the behavioral and psychological 
symptoms of dementia, including aggression and insomnia 
[12], functional dyspepsia [13], stomatitis [14], and periph-
eral neuropathy [15], in patients with dementia and cancer or 
with muscle cramps [16]. Because the frequency of clinical 
use for these five prescriptions has recently increased rap-
idly, and opportunities to be used concomitantly with West-
ern medicines have increased, safety information including 
drug interactions is required in medical practice. In order 
to promote the fostering and evolution of these Kampo 
medicines, we are actively accumulating scientific evidence 
to ensure their effectiveness and safety. Several studies on 
the DDIs or the side-effects of these five Kampo medicines 
have been reported previously, which include information on 
side-effects frequency surveys [17, 18] for YKS and SKT, 
cytochrome P-450 (CYP) [19] for YKS and RKT, and P-gp 
function using ATPase assay [20] or other drug transporter 
polypeptide 2B1 to organic anion-transporting polypeptide 
2B1 [21] for various Kampo medicines. The results suggest 
that the possibility of causing severe pharmacokinetic DDIs 
through some types of drug-metabolizing enzyme and trans-
porter or side-effects is low. However, to our knowledge, 
there is no evidence examining the effects of the five Kampo 
medicines on P-gp function using a Caco-2 permeability 
assay recommended by the Japanese Ministry of Health, 
Labor, and Welfare (MHLW) [22] and the US Food and 
Drug Administration (FDA) [23].
Therefore, in this study, the effects of five Kampo medi-
cines (YKS, RKT, HST, GJG, and SKT) on P-gp drug trans-
port were first examined. Then, the effects of the constituent 
crude drugs and some ingredients in YKS, which showed the 
strongest P-gp inhibitory effect, were further examined to 
clarify the contribution of YKS activity. Finally, the Igut/IC50 
values for the five Kampo medicines were calculated, and 
the DDI risk was objectively evaluated according to the cri-
teria in the DDI guidance of the MHLW [22] and FDA [23].
Materials and methods
Test substances and reagents
The biological activities of the five Kampo medicines and 
the composition of the constituent crude drugs are shown 
in Table 1. In the present study, the dry powdered extracts 
of YKS (Lot No. 321017700), RKT (Lot No. 332003900), 
HST (Lot No. 302149300), GJG (Lot No. 2120107020), and 
SKT (Lot No. 322098500), and seven crude drugs, consti-
tuting YKS {i.e., Uncariae Uncis Cum Ramulus (UUCR; 
Lot No. 2071089010), GR (Lot No. 281013010), Atracty-
lodis Lanceae Rhizoma (ALR; Lot No. 2031005010), Poria 
(Lot No. 2031007010), Angelicae Acutilobae Radix (Lot 
Table 1  Biological activity of the five Kampo medicines used in the present study and the composition of the constituent crude drugs
Kampo medicine Known pharmacological activities Constituent crude drugs (% composition)
Yokukansan Amelioration of behavioral and psychological symptoms of 
dementia [12]
Glycyrrhizae radix (7.4), Atractylodis lanceae rhizoma 
(19.5), poria (19.5), cnidii rhizoma (14.6), Uncariae 
uncis cum ramulus (14.6), Angelicae acutilobae radix 
(14.6), bupleuri radix (9.8)
Rikkunshito Improvement of upper gastrointestinal disorders [13] Atractylodis lanceae rhizoma (18.6), Ginseng radix (18.6), 
Pinelliae tuber (18.6), poria (18.6), zizyphi fructus (9.3), 
citri unshiu pericarpium (9.3), Glycyrrhizae radix (4.7), 
Zingiberis rhizoma (2.3)
Shakuyakukanzoto Amelioration of painful muscle cramps [16] Glycyrrhizae radix (50), Paeoniae radix (50)
Hangeshashinto Reducing chemotherapy-induced oral mucositis [14] Pinelliae tuber (27.0), Scutellariae radix (13.5), Zingiberis 
rhizoma processum (13.5), Glycyrrhizae radix (13.5), 
zizyphi fructus (13.5), Ginseng radix (13.5), coptidis 
rhizoma (5.5)
Goshajinkigan Reducing chemotherapy-induced peripheral neuropathy [15] Rehmanniae radix (17.9), Achyranthis radix (10.7), corni 
fructus (10.7), Dioscoreae rhizoma (10.7), plantaginis 
semen (10.7), alismatis tuber (10.7), poria (10.7), moutan 
cortex (10.7), Cinnamomi cortex (3.6), Aconiti radix 
processa et pulverata (3.6)
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No. 2031002010), Cnidii Rhizoma (Lot No. 2031004010), 
and Bupleuri Radix (Lot No. 2081020010)} were supplied 
by Tsumura & Co. (Tokyo, Japan). They were prepared 
by spray-drying a hot water extract from one crude drug 
or a mixture of several crude drugs. UUCR alkaloids geis-
soschizine methyl ether (GM) and rhynchophylline (RP) 
were obtained from AvaChem Scientific (San Antonio, TX, 
USA) and Tsumura & Co., respectively.
[3H]-Digoxin (26.3–39.8  Ci/mmol),  [3H]-mannitol 
(17.2 Ci/mmol), and ULTIMA Gold scintillation fluid were 
obtained from PerkinElmer Life and Analytical Sciences 
(Waltham, MA, USA). Digoxin was obtained from Alfa 
Aesar (Ward Hill, MA, USA). Mannitol was obtained from 
Wako Pure Chemical Industries (Osaka, Japan). Verapamil 
hydrochloride was obtained from Enzo Life Sciences (Farm-
ingdale, NY, USA).
Fetal bovine serum, nonessential amino acids, penicillin, 
streptomycin, and l-glutamine used for Caco-2 cell culture 
were purchased from Thermo Fisher Scientific (Waltham, 
MA, USA).
Other chemicals were purchased from commercial 
sources.
Test substance solutions
Various concentrations of the five Kampo medicines, seven 
crude drugs, and two ingredients (GM and RP) were pre-
pared by dissolving in dimethyl sulfoxide (DMSO) or a mix-
ture of DMSO and HEPES-buffered HBSS (HBSS-HEPES, 
pH 7.4) and then diluting with HBSS-HEPES buffer. The 
final concentration of DMSO was adjusted to ≤1% (v/v) in 
each study.
Caco‑2 cell culture
Caco-2 cells obtained from the American Type Culture 
Collection (Manassas, VA, USA) were routinely cultured 
in Dulbecco’s Modified Eagle Medium (DMEM; Thermo 
Fisher Scientific), including 10% fetal bovine serum, 1% 
nonessential amino acids, 100 U/ml penicillin, 100 µg/ml 
streptomycin, and 292 µg/ml l-glutamine, and incubated at 
37 °C in an atmosphere with 5%  CO2. They were split three 
times per week at a ratio of 1:4 upon reaching 80–90% con-
fluence to use in the following cell viability and P-gp perme-
ability assays. The cells used in this study were between 25 
and 52 passages.
Cell viability assay
The confluent Caco-2 cells (1.0 × 104 cells/well) were seeded 
into 96-well plates and incubated for 2 days in the same con-
stituent DMEM as described above. The media were then 
replaced with DMEM that included various concentrations 
of test substance or vehicle. Three or more wells were used 
for evaluation of each concentration. After the test sub-
stance-added wells were incubated for 2 h, the supernatant 
was removed, and 90 μl of HBSS-HEPES buffer and 10 μl 
of Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, 
Japan) were then added to the well. The cells were incubated 
for another 2–4 h at 37 °C in a  CO2 incubator and measured 
at 450 nm using a Tecan Infinite M200 plate reader (Manne-
dorf, Switzerland). Cell viability was evaluated as a percentage 
of the absorbance of drug-treated cells relative to that of the 
vehicle-treated control (100% viability).
Digoxin transport assay via P‑gp
Caco-2 cells (2.7 × 104 cells/insert) were seeded into a poly-
ethylene terephthalate insert (0.4 mm pore size; Corning Life 
Sciences, Acton, MA, USA) in 24-well tissue culture plates. 
After culturing for approximately 21 days, the cell monolayer 
insert side was washed with warm phosphate-buffered saline 
(PBS), and the PBS in the apical chamber and the medium 
in the basolateral chamber were replaced with HBSS-HEPES 
buffer.
The transepithelial electrical resistance (TEER) to evalu-
ate the integrity of the cell monolayer was measured using 
the Millicell ER-2 (Millipore, Billerica, MA, USA). For fur-
ther verification of the tight junctions in the monolayer, warm 
HBSS-HEPES buffer containing mannitol (10 µmol/l) and 
 [3H]-mannitol (0.058 µmol/l) was loaded into apical chambers, 
and the monolayer permeability of mannitol was measured in 
the same procedure as that of the following test substances. 
The integrity of a cell monolayer was confirmed by measuring 
the TEER, and mannitol permeability was used for evaluation 
of the test substance.
To evaluate the test substance effect on the permeabil-
ity of digoxin via the cell monolayer, warm HBSS-HEPES 
buffer containing digoxin (10  µmol/l) and  [3H]-digoxin 
(0.025–0.038 µmol/l) was added into either the apical or baso-
lateral chamber in the absence or presence of various concen-
trations of test substances or verapamil (50 µmol/l). Aliquot 
solution in the apical or basolateral chamber was collected 
after incubation at 37 °C for 120 min with slow rotation in the 
horizontal direction and addition of an ULTIMA GOLD scin-
tillation cocktail. The mixture was immediately injected into 
a liquid scintillation counter (AccuFLEX LSC-7200; Hitachi 
Aloka Medical, Tokyo, Japan) to measure the radioactivity.
The apparent permeability (Papp) of digoxin was calculated 
as follows:
Papp =
(
dQ
dt
)
× V
A × C0
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where dQ/dt is the slope of the linear portion of the perme-
ated amount versus time curve (µmol/l/s), A is the effective 
surface area of the Transwell insert (0.3 cm2), C0 is the ini-
tial concentration of the digoxin applied at t = 0 (µmol/l), and 
V is the volume of the receiver chamber (ml).
The efflux ratio to evaluate the P-gp inhibitory effect of 
the test substance was calculated as follows:
where Papp, A→B is the apparent permeability of digoxin from 
the apical-to-basolateral direction and Papp, B→A is that from 
the basolateral-to-apical direction.
The inhibition ratios of P-gp by the test substances were 
determined as follows:
Data analysis
The efflux ratios in each experiment were expressed as the 
mean ± standard deviation (SD). The statistical significance 
was evaluated by one-way analysis of variance (ANOVA) 
and Dunnett’s multiple comparisons test. A P value of < 0.05 
indicated significance.  IC50 values for P-gp inhibition of the 
five Kampo medicines were calculated by non-linear regres-
sion analysis using SAS 9.2 software (SAS Institute, Inc., 
Cary, NC, USA) or from the least square regression line. The 
concentration–response correlative formula and correlation 
coefficient (R2) for each crude drug constituting YKS were 
determined by regression analysis using Excel (Microsoft, 
Redmond, WA, USA).
Results
Cell viability
The viabilities of Caco-2 cells treated with various concen-
trations of test substances are summarized in Supplemen-
tary Table S1. From the results, the concentrations of test 
substances that showed little cell toxicity (i.e., cell viabili-
ties >80%) were used in the digoxin transport assay using a 
Caco-2 cell monolayer.
Effects of test substances on digoxin transport 
across a Caco‑2 cell monolayer
The TEER value of the Caco-2 cell monolayer guarantees 
tight junction formation, which depends on the cell source, 
passage number, number of seeded cells, and culture condi-
tions [24]. Based on this information, the TEER value cor-
responding to our experimental condition was judged to be 
Eﬄux ratio =
Papp,B→A
Papp,A→B
Inhibition ratio (%) = (eﬄux ratiotest substance∕ eﬄux ratiocontrol) × 100.
≥250 Ω cm2. Therefore, Caco-2 cell monolayers showing 
a TEER value of ≥250 Ω cm2 were first selected for this 
experiment. Next, the flux of mannitol across the cell mem-
brane was examined to verify the integrity of the monolayer. 
The permeability of mannitol was < 1.5 × 10−6 cm/s, which 
indicated that the tight junctions of the cell monolayer were 
completed.
Furthermore, to confirm the expression and function of 
P-gp in the completed cell monolayer, transport of digoxin 
via the cell monolayer was investigated. The efflux ratio, 
an index for permeability of digoxin (6.98), was inhib-
ited (0.832) by co-treating a P-gp inhibitor, verapamil 
(50 µmol/l). The inhibition rate was 88.1%, which shows that 
P-gp was expressed in the cell monolayer and functioned.
Figure 1 shows the effects of the five Kampo medicines 
(YKS, RKT, SKT, HST, and GJG) on digoxin transport 
across the cell monolayer. All the Kampo medicines signifi-
cantly inhibited the efflux ratio in a dose-dependent manner 
(YKS, F5,18 = 69.3, P < 0.001; RKT, F5,12 = 129.0, P < 0.001; 
SKT, F5,12 = 12.0, P < 0.001; HST, F6,14 = 35.2, P < 0.001; 
GJG, F5,12 = 32.0, P < 0.001). The  IC50 values of YKS, 
RKT, SKT, HST, and GJG calculated by non-linear regres-
sion analysis were 1.94, 3.36, 10.80, 6.37, and 6.34 mg/ml, 
and the Igut/IC50 values as P-gp inhibition index were 3.4, 
Fig. 1  Inhibitory effects of five Kampo medicines on the efflux ratio 
across the Caco-2 cell monolayer of the P-gp substrate digoxin. 
Data represent the mean ± SD (n = 3–4). One-way ANOVA showed 
that each Kampo medicine significantly inhibited the efflux ratio in 
a concentration-dependent manner. The  IC50 values for P-gp inhibi-
tion were calculated by non-linear regression analysis using SAS 
9.2 software. The Igut/IC50 values were calculated as follows: Igut/
IC50 = Inhibitordose in 250 ml/IC50
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2.4, 0.5, 1.4, and 1.4, respectively. However, the  IC50 values 
of SKT and HST were calculated as the estimated values, 
because both medicines did not show 50% inhibition in the 
examined concentration range.
Next, the P-gp inhibition rates of seven crude drugs 
constituting YKS showing the strongest suppression of 
P-gp were examined. As shown in Fig. 2, four crude drugs 
(ALR, Poria, GR, and UUCR) among the seven constituents 
significantly inhibited the efflux ratio in a concentration-
dependent manner (ALR, F3,12 = 229.0, P < 0.001; Poria, 
F3,12 = 58.4, P < 0.001; GR, F3,12 = 471.0, P < 0.001; 
UUCR, F2,9 = 577.0, P < 0.001). The correlativity was 
observed as y = − 0.031x + 95.264 and the correlation coef-
ficient as (R2) = 0.9537 for ALR, y = − 0.033x + 96.634 
and R2 = 0.9379 for Poria, y = − 0.046x + 104.790 and 
R2 = 0.9757 for GR, and y = − 0.191x + 97.706 and 
R2 = 0.9926 for UUCR, where y is the efflux ratio and x is 
the drug concentration. From these formulas, the  IC50 values 
were calculated to be 1,470 µg/ml for ALR, 1,430 µg/ml 
for Poria, 1,190 µg/ml for GR, and 249 µg/ml for UUCR. 
Other crude drugs (Angelicae Acutilobae Radix, Cnidii Rhi-
zoma, and Bupleuri Radix) had low correlation, and the  IC50 
values could not be determined in the concentration range 
examined.
Table 2 shows the P-gp inhibition rate for each concen-
tration of each constituent crude drug contained in the  IC50 
concentration (1.94 mg/ml, Fig. 1) of YKS to determine the 
contribution of each crude drug to the inhibitory effect of 
YKS. The concentration of each crude drug contained in 
the  IC50 concentration of YKS was obtained from the com-
position ratio of the seven crude drugs constituting YKS. 
The inhibition rate at the concentration of each crude drug 
contained in the  IC50 concentration of the YKS extract was 
calculated using the correlative formulas in Fig. 2. UUCR 
inhibited the majority (53.1%) of the total inhibitory activity 
of the seven crude drugs.
Next, the effects of GM and RP, which are UUCR alka-
loids in YKS, were evaluated using a Caco-2 permeabil-
ity assay (Fig. 3). GM (>10 μmol/l) and RP (100 μmol/l) 
significantly inhibited the efflux ratio (P < 0.001) compared 
to those in the control, and the  IC50 values were 16.5 and 
56.0 µmol/l, respectively.
Fig. 2  Inhibitory effect of four among seven crude drugs constituting 
YKS on the efflux ratio across a Caco-2 cell monolayer of the P-gp 
substrate digoxin. The dose–response correlative formula and correc-
tion coefficient (R2) of each crude drug were determined by regres-
sion analysis. Each data point represents the mean ± SD (n = 4). Con-
centration reactivity was statistically evaluated by one-way ANOVA
Table 2  The P-gp inhibition 
rate of seven crude drugs 
constituting YKS
a Concentration of each crude drug in the  IC50 concentration (1.94 mg/ml) of YKS extract was calculated 
from the composition ratio of seven crude drugs constituting YKS
b The contribution rate of each crude drug was calculated as a percentage of the total inhibition at each con-
centration included in the YKS  (IC50 concentration) by using the correlative formulas described in result 
section and Fig. 2
Crude drug Composition ratio of crude 
drug in YKS (%)
Concentration of crude 
drug in YKS (μg/ml)a
Contribu-
tion rate 
(%)b
Uncariae uncis cum ramulus 14.6 284 53.1
Glycyrrhizae radix 7.4 143 1.7
Atractylodis lanceae rhizoma 19.5 378 15.3
Poria 19.5 378 14.7
Angelicae acutilobae radix 14.6 284 3.0
Cnidii rhizoma 14.6 284 7.4
Bupleuri radix 9.8 189 4.8
Total 100.0 1,940 100.0
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The concentrations of GM and RP were 0.238 nmol/ml 
(0.238 µmol/l) and 0.179 nmol/ml (0.179 µmol/l) in the 
1.94 mg/ml of YKS, respectively. To clarify the contribu-
tions of both ingredients to the inhibitory effect of YKS, 
although the inhibition rate at the concentration of each 
ingredient contained in the YKS extract were examined in 
Fig. 3, both ingredients were found to hardly inhibit P-gp at 
those concentrations (≤1.5% inhibitions).
Discussion
We examined the inhibitory effect of the five Kampo medi-
cines (YKS, RKT, SKT, HST, and GJG) widely used in clin-
ical treatments for various diseases in Japan on P-gp trans-
port of digoxin across a Caco-2 cell monolayer. Djuv and 
Nilsen [25] suggested the importance of measuring the cel-
lular TEER, mannitol transport, and inhibition of verapamil 
on digoxin transport in a cultured cell monolayer to ensure 
the integrity of cell morphology and function in the Caco-2 
permeability assay. In the present study, the monolayer, of 
which the integrity was confirmed by these indices, was used 
for evaluation of the test substance.
The P-gp transporter assay using a completed Caco-2 
cell monolayer showed that all Kampo medicines examined 
inhibited the P-gp transport of digoxin, with YKS showing 
the strongest inhibitory action. Subsequent examination to 
clarify the contribution of the seven crude drugs constituting 
YKS showed that P-gp inhibitory action was observed in 
UUCR, GR, ALR, and Poria (Fig. 2). Although GR has been 
reported to suppress P-gp activity by ATPase assay [20], its 
contribution to the inhibitory activity of YKS was low as 
shown in Table 2. This result was also supported by other 
results, i.e., GR is included in four Kampo medicines (SKT, 
YKS, RKT, and HST) other than GJG. Of these GR-contain-
ing Kampo medicines, the GR content contained in SKT is 
2–7 times greater than those of the other Kampo medicines. 
However, the P-gp inhibitory action of SKT was the weakest 
among the five Kampo medicines  (IC50: 10.80 mg/ml). This 
result suggests that the GR level contained in each Kampo 
medicine may not contribute much to the P-gp inhibitory 
action of the five Kampo medicines, including YKS. On the 
other hand, UUCR is a crude drug that was contained only 
in YKS among the Kampo medicines examined in the pre-
sent study, among which the inhibitory action of UUCR was 
stronger than the others (Fig. 2), and its contribution to the 
inhibitory activity of YKS was 53.1% (Table 2). Therefore, 
the potent P-gp inhibitory effect of YKS may be mainly due 
to the inhibitory action of UUCR, although the possibility 
that the effect may be due to additive or synergistic action 
with other crude drugs, such as GR, cannot be ruled out from 
this experiment.
We further investigated the P-gp inhibitory effect of the 
two major UUCR alkaloids (GM and RP) that were avail-
able for this study in order to to clarify the components 
contributing to the inhibitory activity of UCCR, and found 
that both ingredients had P-gp inhibitory activity. However, 
the P-gp inhibition rate at the GM and RP concentrations 
in the YKS extract powder was slight (≤1.5%), suggesting 
that other ingredients are involved in the inhibitory activity 
of UCCR. Because many other active alkaloids have been 
identified in YKS in addition to GM and RP [26], it is nec-
essary to examine the P-gp inhibitory actions and additive/
synergistic actions of other active alkaloids in the future. In 
addition, P-gp is also expressed in the luminal membrane of 
the blood–brain barrier, in the apical membranes of excre-
tory cells, such as hepatocytes and kidney proximal tubule 
epithelia, and has an important role in the pharmacokinet-
ics, efficacy, safety, or tissue levels of P-gp substrates [6]. 
We previously demonstrated that several UUCR alkaloids, 
including GM and PR, were detected in the plasma of rats 
treated with oral YKS [27]. It will be necessary to clarify the 
effect of these alkaloids on P-gp localized in other organs.
Both the Japanese MHLW [22] and US FDA [23] draft 
DDI guidance state that test drugs having an Igut/IC50 ≥10 
are likely to be P-gp inhibitors. For test substances evalu-
ated as P-gp inhibitors it is stated that more detailed DDI 
tests should be conducted in humans. Therefore, the Igut/
IC50 values for the five Kampo medicines were calculated, 
and the DDI risk was objectively evaluated according to 
the criteria in the DDI guidance. The rates of YKS, RKT, 
SKT, HST, and GJG examined in the present study were 3.4, 
2.4, 0.5, 1.4, and 1.4, respectively. These values were <10, 
which was evaluated as a weak P-gp inhibitory effect that 
does not require further verification in humans, suggesting 
that the DDI risk due to P-gp inhibition for these Kampo 
Fig. 3  Inhibitory effects of GM and RP on the efflux ratio across the 
Caco-2 cell monolayer of the P-gp substrate digoxin. Each data point 
represents the mean ± SD (n = 3). ***P < 0.001 vs vehicle control: con-
centration reactivity was statistically evaluated by Dunnett’s test fol-
lowing one-way ANOVA
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medicines may be low. Furthermore, it has been reported 
that the inhibitory potential of YKS and RKT against P-gp 
was low in an ATPase assay [28] and did not affect the 
plasma pharmacokinetics of digoxin in mice [19]. Ito et al. 
[19] and Soraoka et al. [29] also evaluated the effects of 
several Kampo medicines on CYP3A, which is known to 
have considerable overlap in substrate specificity and tissue 
localization of P-gp [30], and it has been reported that the 
inhibition rate of YKS on metabolic activity was low in mice 
and humans. Combining the above results, the P-gp inhibi-
tory effect appears to be low in all five Kampo medicines 
examined in this study. In other words, in the present five 
Kampo medicines, it is thought that the possibility of drug 
interaction due to the inhibition of P-gp is extremely low in 
combination therapy with Western medicine.
Conclusion
All Kampo medicines examined (YKS, RKT, SKT, HST, 
and GJG) inhibited the P-gp transport of digoxin in a Caco-2 
permeability assay but to a low degree according to the cri-
teria in the DDI draft guidance of the MHLW and FDA. 
These results suggest that the risk of drug interaction due 
to inhibition of P-gp in combination therapy with Western 
medicines is extremely low for these Kampo medicines. This 
finding should provide useful clinical information on the 
safety and efficacy of combinations of Kampo medicines 
and Western medicines.
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